Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07666516

Cardiorenal Syndrome: Characteristics and Prognostic Impact in Advanced Heart Failure

Advanced heart failure (AHF) represents the end stage of chronic heart failure with reduced ejection fraction and affects up to 10% of patients with heart failure. These patients have refractory disease despite optimal guideline-directed medical therapy, and their management is discussed within a multidisciplinary "Heart Team".

Renal dysfunction is highly prevalent in this population. The coexistence of cardiac and renal dysfunction has been classified under the entity of cardiorenal syndrome. Impaired renal function is an independent predictor of adverse cardiovascular and renal outcomes, including death, heart failure decompensation, worsening renal function, and the need for renal replacement therapy. However, patients with AHF remain a particularly complex population, and the lack of longitudinal biological data and limited understanding of the dynamics of cardiorenal syndrome in relation to therapeutic interventions make prognosis assessment and individualized management challenging.

In addition, little is known about renal tubular function in AHF, despite its central role in hydro-electrolytic balance regulation. Biomarkers of tubular injury such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) have shown prognostic value in therapeutic studies, but their relationship with cardiac function and outcomes in advanced heart failure remains insufficiently characterized.

The primary objective of this study is to evaluate renal function parameters and their evolution over time through measurement of glomerular filtration rate (GFR) and assessment of tubular function in patients with advanced heart failure, and to investigate their association with major adverse cardiovascular events.

This is a prospective, single-center RIPH2 cohort study including 100 patients aged 18 to 75 years managed for advanced heart failure at the Louis Pradel Cardiovascular Hospital (Hospices Civils de Lyon, France). Patients will be followed according to standard care at 6, 12, 18, and 24 months. More comprehensive nephrological and cardiological evaluations will be performed at baseline, 12 months, and 24 months. Biobanking and quality-of-life questionnaires will also be conducted during these visits. Blood and urine samples will be collected at baseline and 12 months for NGAL et KIM-1 analysis. In addition, a subgroup of 50 consenting patients without contraindications will undergo multiparametric non-contrast renal MRI combined with tissue sodium quantification using 23Na MRI of the leg.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Advanced Heart Failure Cardio-Renal Syndrome Cardiorenal Syndrome Cardiovascular Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Heart Diseases Heart Failure Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent signed by the patient,
  • Age ≥ 18 years and ≤ 75 years,
  • Patient with advanced heart failure confirmed by criteria of severe cardiac dysfunction documented in a stable condition, with at least one of the following parameters at baseline:
  • LVEF ≤ 35%,
  • Elevated BNP or NT-proBNP levels (>200 ng/L for BNP and >1000 ng/L for NT-proBNP),
  • NYHA class ≥ 3,
  • At least one hospitalization for heart failure decompensation within the past 24 months,
  • Optimized medical treatment for heart failure according to French/European cardiology guidelines at the maximum tolerated dose for >30 days.

Exclusion criteria

  • Presence of severe extracardiac disease with a life expectancy < 1 year,
  • Patient with end-stage renal disease (GFR <15 mL/min/1.73 m²) or on dialysis,
  • History of heart, kidney, or other solid organ transplantation,
  • Patient in cardiogenic shock,
  • INTERMACS profile ≤ 3,
  • Pregnant, parturient, or breastfeeding women*,
  • Individuals deprived of liberty by judicial or administrative decision,
  • Individuals under psychiatric care,
  • Individuals admitted to a health or social institution for purposes other than research,
  • Adults under legal protection (guardianship or curatorship),
  • Individuals not affiliated with a social security system or equivalent coverage.
  • Contraindication to multiparametric renal MRI combined with tissue sodium measurement using non-contrast 23Na MRI of the leg (including inability to undergo MRI as judged by the investigator).

Treatment and study plan

Cardiorenal syndrome follow-up

Other

Patients with cardiorenal syndrome will be followed for 2 years in nephrology and cardiology according to standard of care. In addition, as part of the research, they will complete quality-of-life questionnaires and provide blood, urine, and stool samples for testing and biobanking. An MRI will also be performed for patients participating in the ancillary study.

Primary outcomes

  1. Occurrence of major cardiovascular events during the first 24 months

    Time frame: At 12 and 24 months

    The primary endpoint of this study is the occurrence of major cardiovascular events during the first 24 months: all-cause mortality, heart transplantation, implantation of a ventricular assist device, hospitalization for heart failure, or worsening ambulatory heart failure.

    The association between baseline renal function parameters (GFR, NGA, and KIM-1) and the occurrence of events during the first 24 months will be evaluated, as well as the association between renal function parameters at 12 months and the occurrence of major cardiovascular events between 12 and 24 months.

Secondary outcomes

  1. Blood and urinary levels of NGAL and KIM-1

    Time frame: at baseline and at 12 months

    Blood and urinary measurement of NGAL (neutrophil gelatinase-associated lipocalin) and KIM-1 (kidney injury molecule-1),

  2. Occurrence of major adverse renal events

    Time frame: at baseline, 12 and 24 months

    Occurrence of major adverse renal events during the first 24 months: persistent (>30 days) decline in glomerular filtration rate of >40%, initiation of renal replacement therapy, or death due to renal causes.

    The association between baseline GFR and the occurrence of adverse renal events during the first 24 months will be evaluated, as well as the association between changes in GFR between baseline and 12 months and the occurrence of adverse renal events between 12 and 24 months.

    Occurrence of major adverse renal events during the first 24 months: persistent (>30 days) decline in glomerular filtration rate of >40%, initiation of renal replacement therapy, or death due to renal causes.

    The association between baseline GFR and the occurrence of adverse renal events during the first 24 months will be evaluated, as well as the association between changes in GFR between baseline and 12 months and the occurrence of adverse renal events between 12 and 24 months.

  3. Occurrence of heart failure decompensation events

    Time frame: at baseline, 12 and 24 months

    Occurrence of heart failure decompensation events (hospitalization, ventricular assist device implantation, or outpatient worsening) during the first 24 months. The association between specific biomarkers of renal tubular injury (serum and urinary NGAL and KIM-1) at baseline and heart failure decompensation events during the first 24 months will be analysed, as well as the association between changes in specific biomarkers of renal tubular injury between baseline and 12 months and the occurrence of heart failure decompensation events between 12 and 24 months.

  4. Clinical data collected over a 24-month follow-up period

    Time frame: over 24 months

    Description of the study population over 24 months of follow-up (clinical, paraclinical, therapeutic characteristics, and serious adverse events),

  5. Score of KCCQ questionnaire

    Time frame: at baseline, and at 6, 12, 18, and 24 months

    Each item of KCCQ questionnaire is scored on a 5-point Likert scale and transformed to a 0-100 scale, with higher scores indicating better health status.

  6. Score of Morisky self-questionnaire MMAS-4

    Time frame: at baseline, and at 6, 12, 18, and 24 months,

    Morisky self-questionnaire MMAS-4 is a generic patient-reported questionnaire used to assess medication adherence. The scale consists of four items, each scored as 0 for "Yes" and 1 for "No". The item scores are summed to yield a total score ranging from 0 to 4. Higher scores indicate better medication adherence.

  7. Biomarkers identification

    Time frame: At baseline, 12 months and 24 months

    IBiomarkers identification in biological samples collected in the study biocollection.

  8. Multiparametric renal MRI

    Time frame: at baseline and at 12 months

    Multiparametric renal MRI (BOLD, diffusion, T1 and T2 mapping) in a subgroup of 50 voluntary patients (optional examination)

  9. Tissue sodium measurement

    Time frame: at baseline and at 12 months.

    Tissue sodium measurement using 23Na MRI of the leg in a subgroup of 50 voluntary patients (optional examination)

Study contacts

Contact information is provided by the study sponsor or research team.

Nathan MEWTON, Pr

CONTACT

[email protected]

04 72 35 71 70 ext. +33

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: CARAVEL

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Jun 24, 2026
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.